Innova Captab Limited has informed the Exchange about that the Company has successfully completed the inspection of its Cephalosporin plant, Baddi, Himachal Pradesh conducted by the United Kingdom Medicines and Healthcare products Regulatory Agency ( UK-MHRA ).
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab has successfully completed an inspection of its Cephalosporin manufacturing plant in Baddi, Himachal Pradesh, conducted by the UK Medicines and Healthcare products Regulatory Agency (UK-MHRA) from 18th to 20th August 2025. The inspection concluded with no critical or major observations, which is a strong positive outcome. Passing a UK-MHRA audit without major findings means the plant is cleared to continue supplying pharmaceutical products to the UK market. This also strengthens the company's credibility for regulatory approvals in other regulated markets.
Positive for shareholders — clean UK-MHRA inspection enhances export potential to the UK and other regulated markets, supports revenue growth from Cephalosporin products, and reduces regulatory risk for the plant.